PolyPeptide Group Shares Climb After Report of Takeover Interest
By Adria Calatayud
PolyPeptide Group shares rose after a Bloomberg report that the Swiss contract drug manufacturer attracted takeover interest from private-equity groups including Sweden's EQT and New York-based KKR.
Shares in PolyPeptide climbed 16%, in a session with broad-based losses across European stocks due to the conflict in the Middle East. The rise took the stock's year-to-date gain to around 40%.
Potential suitors are still considering a possible acquisition and there is no certainty that their deliberations would lead to a deal, according to Bloomberg.
PolyPeptide and EQT didn't respond to requests for comment. KKR declined to comment.
The ownership of PolyPeptide--in which a foundation controlled by businessman Frederik Paulsen Jr. holds a 56.10% stake--means any potential private-equity buyer might need to seek a joint ownership model, analysts at RBC Capital Markets wrote in a note to clients.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 13, 2026 04:24 ET (08:24 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
United States